Gilead Sciences (BSP:GILD34) EV-to-Revenue : 3.90 (As of Apr. 26, 2024)

View and export this data going back to 2016. Start your Free Trial

What is Gilead Sciences EV-to-Revenue?

EV-to-Revenue is calculated as enterprise value divided by its revenue. As of today, Gilead Sciences's enterprise value is R$525,586 Mil. Gilead Sciences's Revenue for the trailing twelve months (TTM) ended in Dec. 2023 was R$134,790 Mil. Therefore, Gilead Sciences's EV-to-Revenue for today is 3.90.

The historical rank and industry rank for Gilead Sciences's EV-to-Revenue or its related term are showing as below:

BSP:GILD34' s EV-to-Revenue Range Over the Past 10 Years
Min: 3.34 Med: 4.17 Max: 13.08
Current: 3.66

During the past 13 years, the highest EV-to-Revenue of Gilead Sciences was 13.08. The lowest was 3.34. And the median was 4.17.

BSP:GILD34's EV-to-Revenue is ranked worse than
68.74% of 1027 companies
in the Drug Manufacturers industry
Industry Median: 2.29 vs BSP:GILD34: 3.66

The reason Enterprise Value is used is because Enterprise Value is more real in reflecting how much an investor pays when buying a company. For detais, go to Enterprise Value.

EV-to-Revenue is a similar ratio to PS Ratio, except here Enterprise Value instead of Market Cap is used in the calculation.

As of today (2024-04-26), Gilead Sciences's stock price is R$174.25. Gilead Sciences's Revenue per Share for the trailing twelve months (TTM) ended in Dec. 2023 was R$53.59. Therefore, Gilead Sciences's PS Ratio for today is 3.25.

Gilead Sciences EV-to-Revenue Historical Data

The historical data trend for Gilead Sciences's EV-to-Revenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Gilead Sciences EV-to-Revenue Chart

Gilead Sciences Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

EV-to-Revenue

Get a 7-Day Free Trial

3.68

3.93

4.07

4.61

4.37

Gilead Sciences Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
EV-to-Revenue	Get a 7-Day Free Trial															4.61	4.54	4.19	4.07	4.37

Competitive Comparison of Gilead Sciences's EV-to-Revenue

For the Drug Manufacturers - General subindustry, Gilead Sciences's EV-to-Revenue, along with its competitors' market caps and EV-to-Revenue data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Gilead Sciences's EV-to-Revenue Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Gilead Sciences's EV-to-Revenue distribution charts can be found below:

* The bar in red indicates where Gilead Sciences's EV-to-Revenue falls into.

Gilead Sciences EV-to-Revenue Calculation

EV-to-Revenue is a similar ratio to PS Ratio, except here Enterprise Value instead of Market Cap is used in the calculation.

Gilead Sciences's EV-to-Revenue for today is calculated as:

EV-to-Revenue	=	Enterprise Value (Today)	/	Revenue (TTM)
	=	525586.005	/	134789.605
	=	3.90

Gilead Sciences's current Enterprise Value is R$525,586 Mil.
Gilead Sciences's Revenue for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was R$134,790 Mil.

Gilead Sciences (BSP:GILD34) EV-to-Revenue Explanation

The reason Enterprise Value is used is because Enterprise Value is more real in reflecting how much an investor pays when buying a company. For detais, go to Enterprise Value.

Gilead Sciences's PS Ratiofor today is calculated as:

PS Ratio	=	Share Price (Today)	/	Revenue per Share (TTM)
	=	174.25	/	53.586
	=	3.25

Gilead Sciences's share price for today is R$174.25.
Gilead Sciences's Revenue per Share for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was R$53.59.

Gilead Sciences EV-to-Revenue Related Terms

Thank you for viewing the detailed overview of Gilead Sciences's EV-to-Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.

Gilead Sciences (BSP:GILD34) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Gilead Sciences Inc (BSP:GILD34) » Definitions » EV-to-Revenue

Comparable Companies

Traded in Other Exchanges

GILD:USA GILD:Mexico GILD:Italy GISd:UK 0QYQ:UK GIS:Germany GILD:Austria GILD:Argentina

Address

333 Lakeside Drive, Foster, CA, USA, 94404

Website

https://www.gilead.com

Gilead Sciences develops and markets therapies to treat life-threatening infectious diseases, with the core of its portfolio focused on HIV and hepatitis B and C. The acquisitions of Corus Pharma, Myogen, CV Therapeutics, Arresto Biosciences, and Calistoga have broadened this focus to include pulmonary and cardiovascular diseases and cancer. Gilead's acquisition of Pharmasset brought rights to hepatitis C drug Sovaldi, which is also part of combination drug Harvoni, and the Kite, Forty Seven, and Immunomedics acquisitions boost Gilead's exposure to cell therapy and noncell therapy in oncology.

Gilead Sciences (BSP:GILD34) Headlines

No Headlines